Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community
- Presenting data evaluating LP352 engagement of central 5-HT2C receptors via effects on prolactin, and assessing binding activity and functional agonism of LP352 at the 5-HT2 receptors
- Hosting scientific exhibit highlighting the ongoing Phase 1b/2a PACIFIC Study, and LP352, a novel, highly selective 5-HT2C superagonist in development for rare seizure disorders
“We are committed to improving the lives of people living with rare epilepsies, and are pleased to have a meaningful presence at AES this year. We look forward to presenting data highlighting the intrinsic characteristics of LP352, as well as hosting discussions around our ongoing PACIFIC study and future development plans. We believe that LP352 has the promise to be a best-in-class therapy for a broad range of DEEs, and make a difference in these devastating conditions,” stated Dr.
Presentation & Event Details:
Title: Evaluation of Prolactin as a Useful Pharmacodynamic Tool to Assess Engagement of Central 5-HT2C Receptors by LP352, a Potent and Selective 5-HT2C Agonist
Poster number: 1.290
Date/Time:
Title: Searching for Safer and More Effective Medications in the Management of Seizure Disorders: A 5-HT2C Superagonist
Poster number: 2.260
Date/Time:
Longboard Scientific Exhibit: A Novel 5-HT2C Superagonist for Treatment of Rare Seizure Disorders: LP352 and the PACIFIC Study
Date/Time:
Location: Room 207 A&B,
About
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about LP352’s potential to be a best-in-class therapy, Longboard’s participation in the upcoming 2022 AES annual meeting, Longboard’s clinical and preclinical programs, its ability to develop and deliver therapies, and its focus. For such statements, Longboard claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Longboard’s expectations. Factors that could cause actual results to differ materially from those stated or implied by Longboard’s forward-looking statements are disclosed in Longboard’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20221129005353/en/
Corporate Contact:
Head of Investor Relations
IR@longboardpharma.com
619.592.9775
Source: